Fig. 2: IGF2BP3 promotes transcription of c-Myc target genes by inhibiting the proteasome.
From: The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer
A Heat map of DEGs of c-Myc-targeting genes in control and IGF2BP3 knockdown EC cells. B GSEA analysis of DEGs of c-Myc-targeting genes in control and IGF2BP3 knockdown EC cells. C The effects of IGF2BP3 on c-Myc expression treated with DMSO, MG132 (20 μM), bortezomib (200 nM) and chloroquine (100 nM). D The effects of IGF2BP3 on the half-life of c-Myc detected by WB. E Statistical analysis of the effect of IGF2BP3 on the half-life of c-Myc. F Immunohistochemical staining of IGF2BP3 and c-Myc in 24 patients with endometrial cancer. Scale bar, 10 μm. Data are shown as mean ± SD (n ≥ 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
